$HSDT
HELIUS MEDICAL TECHNOLOGIES, INC.

2021 Form 10-K Financial Statement

#000156459022010124 Filed on March 14, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4 2020
Revenue $500.0K $191.0K $661.0K
YoY Change -24.36% 27.33% 32.2%
Cost Of Revenue $298.0K $201.0K $388.0K
YoY Change -23.2% -35.16% -54.35%
Gross Profit $224.0K -$10.00K $273.0K
YoY Change -17.95% -93.75% -58.0%
Gross Profit Margin 44.8% -5.24% 41.3%
Selling, General & Admin $12.18M $2.089M $9.714M
YoY Change 25.34% -45.17% -41.2%
% of Gross Profit 5435.71% 3558.24%
Research & Development $5.990M $830.0K $4.582M
YoY Change 30.73% -48.13% -43.16%
% of Gross Profit 2674.11% 1678.39%
Depreciation & Amortization $112.0K $103.0K $119.0K
YoY Change -5.88% 3.0% -6.3%
% of Gross Profit 50.0% 43.59%
Operating Expenses $18.37M $2.992M $14.66M
YoY Change 25.29% -45.3% -40.52%
Operating Profit -$18.14M -$3.002M -$14.39M
YoY Change 26.11% -46.68% -40.05%
Interest Expense $10.00K $468.0K $193.0K
YoY Change -94.82% 103.48% -98.63%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $63.00K
YoY Change -100.0% -100.0% -99.56%
Pretax Income -$18.13M -$2.534M -$14.13M
YoY Change 28.32% -52.46% -244.46%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$18.13M -$2.534M -$14.13M
YoY Change 28.32% -52.46% 44.46%
Net Earnings / Revenue -3626.4% -1326.7% -2137.67%
Basic Earnings Per Share -$7.38 -$11.80
Diluted Earnings Per Share -$7.38 -$1.770M -$11.80
COMMON SHARES
Basic Shares Outstanding 2.457M 1.198M
Diluted Shares Outstanding 2.457M 1.198M

Balance Sheet

Concept 2021 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.01M $3.331M $3.331M
YoY Change 230.38% -38.99% -38.99%
Cash & Equivalents $3.331M
Short-Term Investments
Other Short-Term Assets $862.0K $735.0K $735.0K
YoY Change 17.28% 20.49% 20.49%
Inventory $476.0K $389.0K $389.0K
Prepaid Expenses $735.0K
Receivables $66.00K $74.00K $74.00K
Other Receivables $185.0K $156.0K $156.0K
Total Short-Term Assets $12.59M $4.685M $4.685M
YoY Change 168.82% -35.3% -35.29%
LONG-TERM ASSETS
Property, Plant & Equipment $412.0K $486.0K $576.0K
YoY Change -28.47% -31.74% -54.29%
Goodwill $759.0K
YoY Change -38.89%
Intangibles $527.0K
YoY Change -9.45%
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Assets $1.508M $1.862M $1.862M
YoY Change -19.01% -40.05% -40.13%
TOTAL ASSETS
Total Short-Term Assets $12.59M $4.685M $4.685M
Total Long-Term Assets $1.508M $1.862M $1.862M
Total Assets $14.10M $6.547M $6.547M
YoY Change 115.4% -36.73% -36.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.069M $747.0K $747.0K
YoY Change 43.11% -55.43% -55.54%
Accrued Expenses $1.436M $1.337M $1.396M
YoY Change 2.87% -11.98% -17.4%
Deferred Revenue $281.0K
YoY Change -34.65%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.653M $2.424M $2.424M
YoY Change 9.45% -36.24% -36.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $193.0K $252.0K $252.0K
YoY Change -23.41% -64.51% -64.51%
Total Long-Term Liabilities $193.0K $252.0K $252.0K
YoY Change -23.41% -64.51% -64.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.653M $2.424M $2.424M
Total Long-Term Liabilities $193.0K $252.0K $252.0K
Total Liabilities $2.846M $2.676M $2.676M
YoY Change 6.35% -40.69% -40.67%
SHAREHOLDERS EQUITY
Retained Earnings -$118.9M
YoY Change 13.49%
Common Stock $123.9M
YoY Change 11.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.26M $3.871M $3.871M
YoY Change
Total Liabilities & Shareholders Equity $14.10M $6.547M $6.547M
YoY Change 115.4% -36.73% -36.74%

Cashflow Statement

Concept 2021 2020 Q4 2020
OPERATING ACTIVITIES
Net Income -$18.13M -$2.534M -$14.13M
YoY Change 28.32% -52.46% 44.46%
Depreciation, Depletion And Amortization $112.0K $103.0K $119.0K
YoY Change -5.88% 3.0% -6.3%
Cash From Operating Activities -$13.39M -$2.171M -$11.74M
YoY Change 14.06% -52.18% -44.1%
INVESTING ACTIVITIES
Capital Expenditures $54.00K -$49.00K $63.00K
YoY Change -14.29% -45.56% -77.34%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $61.00K
YoY Change -100.0% -100.0% -114.52%
Cash From Investing Activities -$56.00K -$49.00K -$9.000K
YoY Change 522.22% -90.39% -98.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $22.70M $10.65M
YoY Change 113.04% 532.23%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 21.13M 2.911M 9.638M
YoY Change 119.19% 95.37% 483.06%
NET CHANGE
Cash From Operating Activities -13.39M -2.171M -11.74M
Cash From Investing Activities -56.00K -49.00K -9.000K
Cash From Financing Activities 21.13M 2.911M 9.638M
Net Change In Cash 7.674M 691.0K -2.128M
YoY Change -460.62% -119.41% -89.43%
FREE CASH FLOW
Cash From Operating Activities -$13.39M -$2.171M -$11.74M
Capital Expenditures $54.00K -$49.00K $63.00K
Free Cash Flow -$13.44M -$2.122M -$11.80M
YoY Change 13.91% -52.31% -44.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 hsdt Class Of Warrants Or Right Expiration Date
ClassOfWarrantsOrRightExpirationDate
2021-04-30
CY2021Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2020Q2 hsdt Operating Lease Rent Plus Utilities Beginning Date
OperatingLeaseRentPlusUtilitiesBeginningDate
2021-01-31
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M10D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y10D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y6M
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Auditor Firm
AuditorFirmId
243
CY2021 dei Auditor Name
AuditorName
BDOUSA, LLP
CY2021 dei Auditor Location
AuditorLocation
Philadelphia, PA, United States
CY2021Q4 us-gaap Cash
Cash
11005000
CY2020Q4 us-gaap Cash
Cash
3331000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
66000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
74000
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
185000
CY2020Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
156000
CY2021Q4 us-gaap Inventory Net
InventoryNet
476000
CY2020Q4 us-gaap Inventory Net
InventoryNet
389000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
862000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
735000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
4685000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
486000
CY2021Q4 us-gaap Goodwill
Goodwill
763000
CY2020Q4 us-gaap Goodwill
Goodwill
759000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
333000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
527000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
90000
CY2020Q4 us-gaap Other Assets
OtherAssets
1376000
CY2020Q4 us-gaap Assets
Assets
6547000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
747000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1337000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
59000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
281000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2424000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
220000
CY2020Q4 us-gaap Liabilities
Liabilities
2676000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1484362
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1484362
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
123872000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1125000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1099000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6547000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-18132000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-14130000
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-26000
CY2020 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-197000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18158000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14327000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.38
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.80
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.38
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.80
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2456782
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1197774
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
363000
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-22000
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
140000
CY2020 hsdt Provision For Inventory Reserve
ProvisionForInventoryReserve
205000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
62000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
225000
CY2020 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
184000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2456782
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1197774
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
5835000
CY2020 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
819000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2529000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-197000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-14130000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
3871000
CY2021 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2744000
CY2021 hsdt Stock Issued During Period Value Warrant Exercised
StockIssuedDuringPeriodValueWarrantExercised
1318000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2021 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
20000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4252000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-26000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-18132000
CY2021 us-gaap Profit Loss
ProfitLoss
-18132000
CY2020 us-gaap Profit Loss
ProfitLoss
-14130000
CY2020 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
4000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
4252000
CY2021 hsdt Common Shares Issued To A Consultant For Services
CommonSharesIssuedToAConsultantForServices
-20000
CY2021 us-gaap Depreciation
Depreciation
112000
CY2020 us-gaap Depreciation
Depreciation
119000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-18000
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-110000
CY2020 hsdt Gain Loss On Lease Modification
GainLossOnLeaseModification
56000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-30000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4000
CY2021 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
29000
CY2020 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-226000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
87000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-4000
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
127000
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
125000
CY2021 hsdt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-63000
CY2020 hsdt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-253000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
369000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-635000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
194000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-280000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-160000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-174000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13388000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11738000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
54000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
63000
CY2019Q4 us-gaap Goodwill
Goodwill
1242000
CY2020 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
61000
CY2021 us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
2000
CY2020 us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
7000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-56000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
22695000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10653000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2889000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1015000
CY2021 hsdt Proceeds From The Exercise Of Stock Options And Warrants
ProceedsFromTheExerciseOfStockOptionsAndWarrants
1320000
CY2020 hsdt Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
323000
CY2020 hsdt Repayment Of Paycheck Protection Program Loan
RepaymentOfPaycheckProtectionProgramLoan
323000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21126000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9638000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-8000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-19000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7674000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2128000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3331000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5459000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11005000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3331000
CY2021 hsdt Non Cash Share Issuance Costs
NonCashShareIssuanceCosts
476000
CY2021 hsdt Share Issuance Costs Included In Accounts Payable And Accrued Liabilities
ShareIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities
17000
CY2020 hsdt Share Issuance Costs Included In Accounts Payable And Accrued Liabilities
ShareIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities
162000
CY2021 us-gaap Nature Of Operations
NatureOfOperations
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.42%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td> <td valign="top"> <p id="N1_DESCRIPTION_BUSINESS_BASIS_PRESENTATI" style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">DESCRIPTION OF BUSINESS</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Helius Medical Technologies, Inc. (the “Company”), is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license or acquire unique and non-implanted technologies targeted at reducing symptoms of neurological disease or trauma.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company’s product, known as the Portable Neuromodulation Stimulator (“PoNS®”), is an innovative non-surgical medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and is indicated for use in the </span>U.S. <span style="Background-color:#FFFFFF;">as a short term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”), and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. The Company is currently accept</span>ing prescriptions for PoNS in the U.S., and expects the first commercial sales to occur in the near term. PoNS <span style="Background-color:#FFFFFF;">is authorized for sale in Canada for two indications: (i) PoNS is authorized as a short term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy (“PoNS Therapy<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup>”); and (ii) PoNS is authorized for use as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. It has been commercially available in Canada since March 2019. PoNS is authorized for sale as a Class IIa medical device in Australia. The Company is working to establish a distribution partner for Australia but currently does not expect to have commercial sales of PoNS in Australia in 2022.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was incorporated in British Columbia, Canada, on March 13, 2014. On May 28, 2014, the Company completed a continuation via a plan of arrangement whereby the Company moved from being a corporation governed by the British Columbia Corporations Act to a corporation governed by the Wyoming Business Corporations Act. On July 20, 2018, the Company completed its reincorporation from Wyoming to the state of Delaware. The Company is headquartered in Newtown, Pennsylvania. <span style="Background-color:#FFFFFF;color:#000000;"> On December 21, 2018, the Company’s wholly owned subsidiary, NeuroHabilitation Corporation, changed its name to Helius Medical, Inc (“HMI”). On January 31, 2019, the Company formed another wholly owned subsidiary, Helius NeuroRehab, Inc., (“HNR”), a Delaware corporation. On October 10, 2019, the Company formed Helius Canada Acquisition Ltd. (“HCA”), a company incorporated under the federal laws of Canada and a wholly owned subsidiary of Helius Medical Technologies (Canada), Inc. (“HMC”), a company incorporated under the federal laws of Canada, which acquired Heuro Canada, Inc. (“Heuro”) from Health Tech Connex Inc. (“HTC”) on October 30, 2019.</span> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s wholly owned subsidiaries are comprised of HMI, HMC, HCA and HNR.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s Class A common stock, par value $0.001 per share (“common stock”) is listed on the Nasdaq Capital Market (“Nasdaq”). The common stock began trading on the Canadian Securities Exchange on June 23, 2014, under the ticker symbol “HSM” and the trading was subsequently transferred to the Toronto Stock Exchange (the “TSX”) on April 18, 2016. The Company<span style="color:#000000;"> voluntarily delisted from the TSX effective as of the close of trading on September 9, 2021. </span>On April 11, 2018, the common stock began trading on Nasdaq under the ticker symbol “HSDT” after having traded on the OTCQB in the United States under the ticker symbol “HSDT” since February 10, 2015. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Reverse Stock Split</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#231F20;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective after the close of business on December 31, 2020, the Company completed a 1-for-35 reverse stock split of its common stock. <span style="font-family:TimesNewRomanPSMT;color:#000000;">All share and per share amounts in this Annual Report have been reflected on a post-split basis.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Going Concern Uncertainty</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the Company had cash of $11.0 million. For the year ended December 31, 2021, the Company incurred a net loss of $18.1 million and, as of December 31, 2021, its accumulated deficit was $137.0 million. For the year ended December 31, 2021, the Company had $0.5 million of revenue from the commercial sale of products or services. The Company expects to continue to incur operating losses and net cash outflows until it generates a level of revenue to support its cost structure. There is no assurance that the Company will achieve profitable operations, and, if achieved, whether it will be sustained on a continued basis. These factors indicate<span style="Background-color:#FFFFFF;color:#000000;"> substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are filed. The Company’s consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and satisfaction of liabilities in the ordinary course of business; no adjustments have been made relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company not continue as a going concern.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company intends to fund ongoing activities by utilizing its current cash on hand, cash received from the sale of its PoNS device in Canada and the <span style="color:#000000;">U.S. </span>and by raising additional capital through equity or debt financings as well as by using its equity line facility entered </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">into on September 1, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with Lincoln Park Capital Fund, LLC (“Lincoln Park”), which is subject to certain limitations and conditions</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. There can be no assurance that the Company will be successful in raising that additional capital or that such capital, if available, will be on terms that are acceptable to the Company. If the Company is unable to raise sufficient additional capital, the Company may be compelled to reduce the scope of its operations and planned capital expenditures.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks and Uncertainties</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">COVID-19 </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (“COVID-19”) as a global pandemic, which has spread throughout the <span style="color:#000000;">U.S. </span>and around the world. The Company’s business, results of operations and financial condition have been and may continue to be adversely impacted by the COVID-19 pandemic and global economic conditions. The outbreak and spread of COVID-19 has significantly increased economic uncertainty. Authorities implemented, and continue to implement, numerous measures to try to contain COVID-19, such as travel bans and restrictions, quarantines, shelter in place orders, and business shutdowns. The COVID-19 pandemic initially led to the closure of PoNS Authorized clinic locations across Canada. While all clinics have re-opened, as of December 31, 2021, they were all operating at reduced capacity, and patients have been and may continue to be less willing to return to these clinics, impacting our commercial activities and our customer engagement efforts. <span style="color:#000000;">In addition, the resurgence of COVID-19 cases across Canada in the fourth quarter of 2020 and first half of 2021 led to further restrictions on clinic activities. However, the rate of vaccination increased throughout all provinces throughout 2021 facilitating the lifting of some of the previously imposed restrictions. Moreover, the Company’s ability to conduct its ongoing clini</span>cal experience programs and clinical trials has been and may be impaired due to trial participants’ attendance being adversely affected by COVID-19. In addition, the COVID-19 pandemic has and may continue to cause delays in the Company’s suppliers’ ability to ship materials that the Company relies upon as well as manufacturing delays as the result of labor shortages. Two of the Company’s suppliers experienced significant labor shortages as a result of COVID-19 from the end of November 2021 through early January 2022 which reduced the available resources needed to build and test product resulting in production delays of the PoNS devices. Disruptions in business or governmental operations due to COVID-19 may delay the timing for the submission and approval of the Company’s marketing applications with regulatory agencies. Further, the economic impact of the COVID-19 pandemic could affect the Company’s ability to access the public markets and obtain necessary capital in order to properly capitalize and continue its operations. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The extent to which the COVID-19 pandemic <span style="color:#000000;">will continue to </span>impact the Company’s business, including its U.S. commercial launch and sales in Canada, as well as the Company’s results of operations and its financial condition will depend on future developments, which are highly uncertain and cannot be predicted. <span style="color:#000000;">The Company does not yet know the full extent of the impact of COVID-19 on its future business, operations or the global economy as a whole.</span></p>
CY2021 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2014-03-13
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-35
CY2020 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
35
CY2021Q4 us-gaap Cash
Cash
11000000.0
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-18100000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-137000000.0
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
500000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosure of contingent assets and liabilities. Significant estimates include the assumptions used in the valuation of the fair value-pricing model for stock-based compensation, derivative financial instruments and deferred income tax asset valuation allowance. Financial statements include estimates, which, by their nature, are uncertain. Actual results could differ from those estimates.</p>
CY2021Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
900000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to credit risk with respect to its cash. Amounts invested in such instruments are limited by credit rating, maturity, industry group, investment type and issuer. The Company maintains cash in excess of federally insured limits in certain banks. However, the Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk related to cash. The Company seeks to maintain safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements and a competitive after-tax rate of return.</p>
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
400000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
400000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1000000
CY2020Q4 hsdt Rent Deposits Receivable
RentDepositsReceivable
18000000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1000000
CY2021 us-gaap Inventory Write Down
InventoryWriteDown
0
CY2020 us-gaap Inventory Write Down
InventoryWriteDown
205000
CY2020 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
-503000
CY2020 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
20000
CY2020Q4 us-gaap Goodwill
Goodwill
759000
CY2021 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
4000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
171000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
160000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
528000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
440000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
32000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
44000
CY2021Q4 us-gaap Inventory Gross
InventoryGross
731000
CY2020Q4 us-gaap Inventory Gross
InventoryGross
644000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
255000
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
255000
CY2021Q4 us-gaap Inventory Net
InventoryNet
476000
CY2020Q4 us-gaap Inventory Net
InventoryNet
389000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
650000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
689000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
241000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
203000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
409000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
486000
CY2021 us-gaap Depreciation
Depreciation
112000
CY2020 us-gaap Depreciation
Depreciation
119000
CY2021Q4 us-gaap Goodwill
Goodwill
763000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
740000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
407000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
333000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
972000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
445000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
527000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
185000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
123000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
25000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
333000
CY2021Q4 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P12M
CY2021Q4 hsdt Number Of Operating Lease
NumberOfOperatingLease
1
CY2021Q2 hsdt Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
68351
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote per share
CY2021 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2021Q4 hsdt Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
2025
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-18132000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-14130000
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2456782
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1197774
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.38
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-11.80
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1265400
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
455631
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 hsdt Fair Value Of Warrants Liability
FairValueOfWarrantsLiability
5000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4252000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
65.23
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
593924
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
99018
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
236.63
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
42988
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
15.20
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
28448
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
210.57
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
159.33
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.89
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
61.55
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
214
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.50
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
669117
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
37.36
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
281435
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2529000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
712000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
496000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
174000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
292000
CY2021Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
23000
CY2020Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
133000
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
10000
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
12000
CY2021Q4 hsdt Accrued Franchise Fee Current
AccruedFranchiseFeeCurrent
193000
CY2021Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
258000
CY2020Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
347000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
63000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
57000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1433000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1337000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-16589000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-12362000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1543000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1768000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18132000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14130000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18132000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14130000
CY2021 hsdt Income Tax Reconciliation Expected Income Tax Recovery
IncomeTaxReconciliationExpectedIncomeTaxRecovery
-3808000
CY2020 hsdt Income Tax Reconciliation Expected Income Tax Recovery
IncomeTaxReconciliationExpectedIncomeTaxRecovery
-2967000
CY2020 hsdt Income Tax Reconciliation Change In Derivative Liability
IncomeTaxReconciliationChangeInDerivativeLiability
-1000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
810000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
415000
CY2021 hsdt Income Tax Reconciliation Nondeductible Expense Change In Other Permanent Difference
IncomeTaxReconciliationNondeductibleExpenseChangeInOtherPermanentDifference
-103000
CY2020 hsdt Income Tax Reconciliation Nondeductible Expense Change In Other Permanent Difference
IncomeTaxReconciliationNondeductibleExpenseChangeInOtherPermanentDifference
-21000
CY2021 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-85000
CY2020 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-97000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3186000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2671000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27514000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
24576000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
987000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
882000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1715000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1616000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1006000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1099000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
31222000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
28173000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
39600000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
64900000
CY2021 hsdt Operating Loss Carryforwards Expiration Starting Year
OperatingLossCarryforwardsExpirationStartingYear
2033
CY2021 hsdt Operating Loss Carryforwards Expiration Ending Year
OperatingLossCarryforwardsExpirationEndingYear
2041
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
58600000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
39600000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
64900000
CY2017Q3 hsdt Lease Monthly Rent Plus Utilities Expense
LeaseMonthlyRentPlusUtilitiesExpense
20000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3000
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.072
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3000
CY2020Q2 hsdt Decrease In Operating Lease Right Of Use Asset Partial Termination
DecreaseInOperatingLeaseRightOfUseAssetPartialTermination
400000
CY2020Q2 hsdt Decrease In Operating Lease Liability
DecreaseInOperatingLeaseLiability
400000
CY2020Q2 hsdt Operating Lease Commencement Date
OperatingLeaseCommencementDate
2020-07-01
CY2020Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-06-30
CY2020Q2 hsdt Operating Lease Option To Extend Lease Term
OperatingLeaseOptionToExtendLeaseTerm
P6M
CY2020Q2 hsdt Lease Monthly Rent Plus Utilities Expense
LeaseMonthlyRentPlusUtilitiesExpense
5000
CY2020Q2 hsdt Operating Lease Annual Increase In Rental Percentage
OperatingLeaseAnnualIncreaseInRentalPercentage
0.03
CY2021Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-09-30
CY2021Q1 hsdt Expected Lease Termination Date
ExpectedLeaseTerminationDate
2021-06-30
CY2021 hsdt Operating Lease Extending Commencement Description
OperatingLeaseExtendingCommencementDescription
The Company extended month to month commencing October 1, 2021
CY2021Q4 hsdt Office Space
OfficeSpace
1780
CY2021Q4 hsdt Operating Lease Commencement Date
OperatingLeaseCommencementDate
2022-01-01
CY2021Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2025-03-31
CY2021Q4 hsdt Rent And Utilities Amount
RentAndUtilitiesAmount
4000
CY2021Q4 hsdt Percentage Of Increase Decrease In Rent And Utilities
PercentageOfIncreaseDecreaseInRentAndUtilities
0.03
CY2021 us-gaap Lessee Operating Lease Option To Terminate
LesseeOperatingLeaseOptionToTerminate
the Company’s assessment of the lease term of the Lease Amendment changed from terminating on June 30, 2022 to terminating on January 15, 2022
CY2021Q4 hsdt Operating Lease Option To Extend Lease Term Date
OperatingLeaseOptionToExtendLeaseTermDate
2022-01-15
CY2021Q4 hsdt Decrease In Operating Lease Right Of Use Asset Partial Termination
DecreaseInOperatingLeaseRightOfUseAssetPartialTermination
29000
CY2021Q4 hsdt Decrease In Operating Lease Liability
DecreaseInOperatingLeaseLiability
29000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
8000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
107000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
63000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
253000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y14D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.033
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
59000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
91000

Files In Submission

Name View Source Status
0001564590-22-010124-index-headers.html Edgar Link pending
0001564590-22-010124-index.html Edgar Link pending
0001564590-22-010124.txt Edgar Link pending
0001564590-22-010124-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gs0j3otiohyz000001.jpg Edgar Link pending
gs0j3otiohyz000002.jpg Edgar Link pending
gs0j3otiohyz000003.jpg Edgar Link pending
gs0j3otiohyz000004.jpg Edgar Link pending
hsdt-10k_20211231.htm Edgar Link pending
hsdt-10k_20211231_htm.xml Edgar Link completed
hsdt-20211231.xsd Edgar Link pending
hsdt-20211231_cal.xml Edgar Link unprocessable
hsdt-20211231_def.xml Edgar Link unprocessable
hsdt-20211231_lab.xml Edgar Link unprocessable
hsdt-20211231_pre.xml Edgar Link unprocessable
hsdt-ex211_8.htm Edgar Link pending
hsdt-ex231_6.htm Edgar Link pending
hsdt-ex311_7.htm Edgar Link pending
hsdt-ex312_9.htm Edgar Link pending
hsdt-ex321_10.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending